Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2024
Jul. 31, 2023
Income Statement [Abstract]        
Revenue $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161
Research and development expenses (including non-cash stock-based compensation expenses of $462, $520, $1,471 and $1,517, respectively) 1,925 1,088 4,920 3,154
General and administrative expenses (including non-cash stock-based compensation expenses of $717, $697, $2,228 and $1,990, respectively) 1,667 1,756 5,748 4,855
Total operating costs and expenses 3,592 2,844 10,668 8,170
Loss from operations (3,592) (2,844) (10,668) (7,960)
Interest income 277 296 883 751
Net loss (3,315) (2,548) (9,785) (7,209)
Less: Net loss attributable to noncontrolling interest (38) (37) (114) (88)
Net loss attributable to common shareholders $ (3,277) $ (2,511) $ (9,671) $ (7,121)
Net loss per common share attributable to common shareholders:        
Basic $ (0.10) $ (0.08) $ (0.30) $ (0.23)
Diluted $ (0.10) $ (0.08) $ (0.30) $ (0.23)
Weighted average common shares outstanding:        
Basic 32,054 30,974 31,804 30,941
Diluted 32,054 30,974 31,804 30,941